Alterity Therapeutics Limited

Alterity Therapeutics Limitedverified

ATHE

Price:

$1.1401

Market Cap:

$15.86M

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.[Read more]

Industry

Biotechnology

IPO Date

2003-09-29

Stock Exchange

NASDAQ

Ticker

ATHE

The PE Ratio as of November 2024 (TTM) for Alterity Therapeutics Limited (ATHE) is -0.56

According to Alterity Therapeutics Limited’s latest financial reports and current stock price. The company's current PE Ratio is -0.56. This represents a change of -99.93% compared to the average of -816.27 of the last 4 quarters.

Alterity Therapeutics Limited (ATHE) Historical PE Ratio (quarterly & annually)

How has ATHE PE Ratio performed in the past?

The mean historical PE Ratio of Alterity Therapeutics Limited over the last ten years is -2078.49. The current -0.56 PE Ratio has changed -97.31% with respect to the historical average. Over the past ten years (40 quarters), ATHE's PE Ratio was at its highest in in the March 2024 quarter at -568.54. The PE Ratio was at its lowest in in the September 2014 quarter at -28248.74.

Quarterly (TTM)
Annual

Average

-2078.49

Median

-1462.32

Minimum

-6264.95

Maximum

-736.27

Alterity Therapeutics Limited (ATHE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Alterity Therapeutics Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 77.62%

Maximum Annual PE Ratio = -736.27

Minimum Annual Increase = -52.43%

Minimum Annual PE Ratio = -6264.95

Quarterly (TTM)
Annual
YearPE RatioChange
2024-1307.7777.62%
2023-736.27-35.55%
2022-1142.40-52.43%
2021-2401.5236.12%
2020-1764.3065.70%
2019-1064.73-13.02%
2018-1224.08-24.29%
2017-1616.88-50.43%
2016-3261.98-47.93%
2015-6264.9535.33%

Alterity Therapeutics Limited (ATHE) Average PE Ratio

How has ATHE PE Ratio performed in the past?

The current PE Ratio of Alterity Therapeutics Limited (ATHE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1062.15

5-year avg

-1470.45

10-year avg

-2078.49

Alterity Therapeutics Limited (ATHE) PE Ratio vs. Peers

How is ATHE’s PE Ratio compared to its peers?

Alterity Therapeutics Limited’s PE Ratio is greater than Anebulo Pharmaceuticals, Inc. (-5.95), greater than PMV Pharmaceuticals, Inc. (-1.73), less than AN2 Therapeutics, Inc. (-0.50), greater than Eliem Therapeutics, Inc. (-2.42), less than HCW Biologics Inc. (-0.42), greater than Protara Therapeutics, Inc. (-1.35), less than Vaccinex, Inc. (-0.33), greater than Monopar Therapeutics Inc. (-8.34), greater than Miromatrix Medical Inc. (-3.41), greater than Surrozen, Inc. (-0.70), less than NovaBay Pharmaceuticals, Inc. (-0.08), greater than ARCA biopharma, Inc. (-58.03), less than Quoin Pharmaceuticals, Ltd. (-0.44), greater than Artelo Biosciences, Inc. (-0.83), less than Adial Pharmaceuticals, Inc. (-0.34), less than TransCode Therapeutics, Inc. (-0.20), less than Aditxt, Inc. (-0.02), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.05), less than Avenue Therapeutics, Inc. (-0.24),

Build a custom stock screener for Alterity Therapeutics Limited (ATHE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alterity Therapeutics Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Alterity Therapeutics Limited (ATHE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Alterity Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Alterity Therapeutics Limited's PE Ratio?

How is the PE Ratio calculated for Alterity Therapeutics Limited (ATHE)?

What is the highest PE Ratio for Alterity Therapeutics Limited (ATHE)?

What is the 3-year average PE Ratio for Alterity Therapeutics Limited (ATHE)?

What is the 5-year average PE Ratio for Alterity Therapeutics Limited (ATHE)?

How does the current PE Ratio for Alterity Therapeutics Limited (ATHE) compare to its historical average?